Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status

• DOI: 10.1136/rmdopen-2023-003884
• Publication Date: 2024-05-09T17:20:47Z
• Authors: Martin Rudwaleit; Atul Deodhar; Lars Bauer; Lianne Gensler; Bengt Hoepken; Thomas Kumke; Simone Emanuele A...; Mindy Kim; Walter Maksymowych
• Keywords: Certolizumab pegol; Axial spondyloarthritis; Baseline (sea)

There is a paucity of data on long-term clinical responses in patients with non-radiographic axial spondyloarthritis (nr-axSpA) based their baseline objective signs inflammation such as MRI or C-reactive protein (CRP) levels. This study reports outcomes up to 3 years the C-axSpAnd trial, including safety follow-up extension (SFE) from Weeks 52 156, stratified by patients' and CRP status. (NCT02552212) was phase 3, multicentre that evaluated certolizumab pegol (CZP) active nr-axSpA who had sacroiliitis and/or elevated CRP. In this post hoc analysis, efficacy are reported Week 156 for according status at 0 (MRI+/CRP-, MRI-/CRP+ MRI+/CRP+). Across all outcome measures, major improvement Ankylosing Spondylitis Disease Activity Score (ASDAS-MI) Assessment SpondyloArthritis international Society criteria ≥40% response (ASAS40), were generally sustained SFE 156. MRI+/CRP+ showed numerically higher comparable relative MRI+/CRP- 156; however, three subgroups demonstrated substantial improvements (in CZP-randomised patients, ASDAS-MI [observed case]: MRI+/CRP+: 73.1%, MRI-/CRP+: 52.2%, MRI+/CRP-: 30.4%; ASAS40: 76.9%, 62.5%, 65.2%). inflammation, achieved after 1 year across MRI+/CRP+, subgroups.